Tempus AI (TEM) stock & equity tools

Tempus AI, Inc. is an American health technology company founded in 2015 by Eric Lefkofsky in Chicago, Illinois. It was established by Lefkofsky soon after his wife was diagnosed with breast cancer. Tempus uses data and artificial intelligence (AI) to create precision medicine services, including diagnostics, for oncology, cardiology, radiology, and depression. The company went public on the Nasdaq on June 14, 2024, under the ticker symbol "TEM."

Source: Wikipedia (CC BY-SA 4.0)

Eric Lefkofsky founded Tempus in Chicago in 2015 after his wife's breast cancer diagnosis exposed how little structured data oncologists could pull on demand. The platform now links clinical records with molecular sequencing across oncology, cardiology, and neuropsychiatry, and sells AI-enabled diagnostics back to physicians and pharma. Tempus listed on NASDAQ as TEM in June 2024 at $37. Revenue hit $1.27B in 2025 (up 83%), and a three-year AstraZeneca and Pathos collaboration adds $200M in data and model-development fees toward a multimodal oncology foundation model.

Sources: en.wikipedia.org · investors.tempus.com

Equity comp at Tempus AI

• RSUs use single-trigger vesting: shares become yours as each portion vests on schedule, and the value is taxed as ordinary income at that point. No IPO or acquisition is required.

Researched 2026-05-07.